Ignite Creation Date:
2024-05-05 @ 11:57 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00181155
Status:
COMPLETED
Last Update Posted:
2017-05-30
First Post:
2005-09-12
Brief Title:
Intravenous Allopurinol in Heart Failure
Sponsor:
Johns Hopkins University
Organization:
Johns Hopkins University
Study Overview
Official Title:
Effects of Xanthine Oxidase Inhibition on Mechano-Energetic Coupling in Heart Failure
Status:
COMPLETED
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study tests the hypothesis that allopurinol a xanthine oxidase inhibitor improves heart metabolism in patients with heart failure
Detailed Description:
Xanthine oxidase have been reported to improve mechano-energetic coupling in failing hearts The investigators developed a means to directly measure creatine kinase flux the major energy reserve of the heart in the human heart exploiting new magnetic resonance technologies
The investigators propose to study 10 healthy subjects and up to 25 with heart failure dilated cardiomyopathy before and after a single 300mg IV infusion of allopurinol
The investigators propose to study 10 healthy subjects and up to 25 with heart failure dilated cardiomyopathy before and after a single 300mg IV infusion of allopurinol
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 5R01HL061912-14 | NIH | None | httpsreporternihgovquickSearch5R01HL061912-14 |